In addition, FOXO1 also inhibits the proliferation and growth of cancer cells in chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) [28,29], thereby exerting antitumor effects in hematological tumors. Here, FOXO1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.